.Pharmacolibrary.Drugs.D_Dermatologicals.D07A_CorticosteroidsPlain.D07AB19_Dexamethasone.Dexamethasone_1 .Pharmacolibrary.Drugs.D_Dermatologicals.D07A_CorticosteroidsPlain.D07AB19_Dexamethasone.Dexamethasone_1| name: | Dexamethasone_1 |
| ATC code: | D07AB19_1 | route: | intravenous |
| n-compartments | 2 |
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs. It is used as an anti-inflammatory and immunosuppressant in conditions such as allergies, asthma, rheumatoid arthritis, severe COVID-19, various cancers, and cerebral edema. Dexamethasone is approved and widely used both in hospital and outpatient settings.
PK parameters for intravenous bolus administration in healthy adults.
Li, L, et al., & Endeman, H (2023). Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role?. Journal of critical care 78 154395–None. DOI:10.1016/j.jcrc.2023.154395 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37542750
Guthrie, S (1991). The impact of dexamethasone pharmacokinetics on the DST: a review. Psychopharmacology bulletin 27(4) 565–576. PUBMED:https://pubmed.ncbi.nlm.nih.gov/1813902
Nijstad, AL, et al., & Zwaan, CM (2022). Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30(12) 9991–9999. DOI:10.1007/s00520-022-07423-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36287279